📖
Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.
Calcaterra IL, De Luca C, Valletta LJ, D'Errico G, Ferrandino M, Cardiero G, Di Taranto MD, Fortunato G, Iannuzzo G, Tufano A, Di Minno M

Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.

Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in Intern Emerg Med.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Real-world lipid outcomes after switching PCSK9-targeting therapies in heterozygous familial hypercholesterolemia: the SHIFT-FH study.
Author / Organization Calcaterra IL, De Luca C, Valletta LJ, D'Errico G, Ferrandino M, Cardiero G, Di Taranto MD, Fortunato G, Iannuzzo G, Tufano A, Di Minno M
Subject & Discipline Intern Emerg Med
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-16513
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »